GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) » Definitions » EV-to-FCF

Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) EV-to-FCF : -18.07 (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biohaven Pharmaceutical Holding Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biohaven Pharmaceutical Holding Co's Enterprise Value is $11,087.2 Mil. Biohaven Pharmaceutical Holding Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was $-613.5 Mil. Therefore, Biohaven Pharmaceutical Holding Co's EV-to-FCF for today is -18.07.

The historical rank and industry rank for Biohaven Pharmaceutical Holding Co's EV-to-FCF or its related term are showing as below:

BHVN' s EV-to-FCF Range Over the Past 10 Years
Min: -18.07   Med: -8.25   Max: -2.38
Current: -18.07

During the past 7 years, the highest EV-to-FCF of Biohaven Pharmaceutical Holding Co was -2.38. The lowest was -18.07. And the median was -8.25.

BHVN's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 4.27 vs BHVN: -18.07

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Biohaven Pharmaceutical Holding Co's stock price is $14.08. Biohaven Pharmaceutical Holding Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $-14.820. Therefore, Biohaven Pharmaceutical Holding Co's PE Ratio for today is At Loss.


Biohaven Pharmaceutical Holding Co EV-to-FCF Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co EV-to-FCF Chart

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-FCF
Get a 7-Day Free Trial -8.83 -6.81 -6.65 -6.88 -11.46

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.57 -10.85 -11.46 -12.91 -17.23

Competitive Comparison of Biohaven Pharmaceutical Holding Co's EV-to-FCF

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biohaven Pharmaceutical Holding Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's EV-to-FCF falls into.



Biohaven Pharmaceutical Holding Co EV-to-FCF Calculation

Biohaven Pharmaceutical Holding Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11087.211/-613.518
=-18.07

Biohaven Pharmaceutical Holding Co's current Enterprise Value is $11,087.2 Mil.
Biohaven Pharmaceutical Holding Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-613.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biohaven Pharmaceutical Holding Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=14.08/-14.820
=At Loss

Biohaven Pharmaceutical Holding Co's share price for today is $14.08.
Biohaven Pharmaceutical Holding Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.820.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Biohaven Pharmaceutical Holding Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co (Biohaven Pharmaceutical Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Elyse Stock officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
James Engelhart officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director, 10 percent owner 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC., 125 SPRING STREET, LEXINGTON MA 02421
Kimberly Gentile officer: VP of Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Robert Berman officer: Chief Medical Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John Tilton officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054